7月31日，德康医疗夜盘上涨7.28%，报79.97美元/股。消息面上，公司盘后公布第二季度财报，业绩全面超出市场预期，并上调全年营收指引，成为股价上涨的核心催化剂。
具体数据方面，Q2调整后每股收益0.70美元，大幅超越分析师一致预期的0.61美元，同比增长45.83%；营收13.08亿美元，超预期的12.90亿美元，同比增长约13%。公司同时将全年营收指引上调至51.8亿至52.5亿美元，此前区间下限为51.6亿美元。连续血糖监测仪市场需求持续旺盛，叠加Stelo非处方产品向更广泛消费健康市场的拓展，推动公司业绩持续增长。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.